Share This Page
Drug Price Trends for NDC 27241-0049
✉ Email this page to a colleague
Average Pharmacy Cost for 27241-0049
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ENTACAPONE 200 MG TABLET | 27241-0049-10 | 0.34379 | EACH | 2025-12-17 |
| ENTACAPONE 200 MG TABLET | 27241-0049-10 | 0.32157 | EACH | 2025-11-19 |
| ENTACAPONE 200 MG TABLET | 27241-0049-10 | 0.31921 | EACH | 2025-10-22 |
| ENTACAPONE 200 MG TABLET | 27241-0049-10 | 0.33470 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 27241-0049
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 27241-0049
Introduction
The drug with National Drug Code (NDC) 27241-0049 is a pharmaceutical product that has garnered attention within the healthcare and biotech sectors owing to its therapeutic profile and market potential. This analysis provides a comprehensive review of its current market dynamics, competitive landscape, regulatory status, and future pricing projections. It aims to equip industry stakeholders—including formulary managers, investors, and healthcare providers—with insightful, data-driven intelligence to guide strategic decision-making.
Product Overview
NDC 27241-0049 refers to a specific formulation—most likely a branded or generic drug, the details of which are essential in contextualizing its market performance. For the purpose of this analysis, the drug is assumed to be a novel therapy or a biosimilar, which influences its commercialization strategy and pricing trajectory.
Note: Precise product specifics such as active ingredient, indication, formulation, and therapeutic class are critical for accurate market assessments. As these details are not explicitly provided, the following analysis employs industry-standard assumptions aligned with similar drugs in its class.
Regulatory Status and Market Entry
The regulatory clearance of NDC 27241-0049 significantly impacts its market penetration and pricing. If recently approved by the FDA, it likely commands premium pricing initially, especially if indicated for a high-impact or orphan disease [1].
- FDA Approval: Recent approvals lead to high initial prices, driven by exclusivity rights under patents or market exclusivity provisions.
- Orphan Drug Designation: If applicable, offers price premiums and market exclusivity for up to 7 years.
- Companion Diagnostics: Approval of diagnostics in tandem can influence market adoption rates and pricing strategies.
Market Landscape & Competitive Environment
Therapeutic Area Analysis
The drug's therapeutic category heavily influences market dynamics:
- High Demand and Growth Potential: Oncology, rare diseases, and certain neurology indications exhibit rapid growth driven by unmet medical needs.
- Market Saturation: Presence of established therapies can suppress pricing unless the product offers significant clinical advantages.
Competitor Overview
- Existing Competitors: Multiple generics or biosimilars could exert downward pricing pressure.
- Innovator Edge: New or patented therapies often command premium prices until generics enter.
- Market Penetration: Adoption heavily depends on clinical trial outcomes, payer acceptance, and healthcare provider preference.
Current Pricing Trends
Historical Price Movements
The initial launch prices for drugs in similar categories have ranged between $X,XXX to $XX,XXX per treatment course or per unit, influenced by factors such as:
- Manufacturing costs
- R&D expenditures
- Market exclusivity
- Reimbursement landscape
Pricing Drivers
- Reimbursement Policies: Payer willingness to reimburse influences the price ceiling.
- Value-Based Pricing: Demonstrations of superior efficacy or safety can justify higher prices.
- Market Access Strategies: Tiered pricing and patient assistance programs are common in maintaining competitive positioning.
Price Projections (2023-2028)
Based on current market trends and projections in the therapeutic area, forecasts suggest:
| Year | Estimated Average Wholesale Price (AWP) | Price Trends & Rationale |
|---|---|---|
| 2023 | $X,XXX – $XX,XXX | Launch price, premium justified by patent exclusivity. |
| 2024 | Slight decrease (~5-10%) | Entry of biosimilars or generics begins to apply downward pressure. |
| 2025 | Stabilization or further decline (~10%) | Mature market with established payer negotiations. |
| 2026-2028 | Potential pricing restructuring due to market competition and value-based agreements. | Price stabilization with targeted discounts or reimbursement adjustments. |
Note: These are estimations subject to change based on clinical results, regulatory updates, and market responses.
Factors Influencing Future Price Dynamics
- Patent Expiry or Market Genericization: Potential catalytic factor for significant price reductions post-patent expiry.
- Regulatory Changes: Policy shifts favoring biosimilar entry or value-based pricing models.
- Market Adoption Rates: Accelerated uptake due to demonstrated superior efficacy may sustain or elevate prices.
- Payer Negotiations and Reimbursement Policies: Budget constraints and formulary positioning can modify negotiated prices.
Implications for Stakeholders
- Pharmaceutical Manufacturers: Opportunities for premium pricing during initial exclusivity, then strategic adjustments post-patent.
- Investors: Anticipate near-term high margins followed by potential declines; investing in R&D or marketing strategies can influence long-term profitability.
- Healthcare Providers and Payers: Focus on balancing clinical benefits with cost management; strategic formulary placements can impact overall utilization and reimbursement outcomes.
Key Challenges and Opportunities
- Challenge: Competition from biosimilars or generics reducing prices over time.
- Opportunity: Demonstrating clinical superiority and securing value-based agreements to maintain pricing premium.
- Challenge: Regulatory hurdles or delays affecting market speed.
- Opportunity: Early engagement with regulators and payers to streamline approval and reimbursement processes.
Conclusion
NDC 27241-0049 is positioned within a competitive, rapidly evolving market landscape. Its initial pricing is likely to reflect its innovative nature, brand advantages, and regulatory exclusivities. However, pricing pressures will intensify as competitors emerge. Strategic value demonstration, robust market access, and lifecycle management will be critical to sustaining optimal pricing and market share.
Key Takeaways
- Market Entry: Expect high initial prices buoyed by exclusivity; early negotiation with payers is crucial.
- Competitive Dynamics: Biosimilar and generic entries pose significant downward pressure over 3-5 years.
- Pricing Strategy: Invest in clinical data showcasing value to justify premium pricing; consider flexible pricing models aligned with outcomes.
- Regulatory Trends: Monitor policy shifts towards biosimilar adoption and value-based pricing.
- Long-term Outlook: Expect stabilization as the market matures; product differentiation and real-world data will determine future pricing trajectories.
FAQs
1. How will biosimilar entries impact the price of NDC 27241-0049?
Biosimilar competition typically leads to a substantial price decline, often between 20% and 50%, depending on market adoption rates and patent status.
2. Are there special regulatory considerations influencing the pricing of this drug?
Yes. If designated as an orphan drug or under patent protection, pricing may be premium and less susceptible to immediate competition. Regulatory pathways, such as accelerated approvals or supplemental indications, also influence pricing strategies.
3. What are the primary factors driving the drug's market demand?
Demand is driven by clinical efficacy, safety profile, unmet medical needs, indication prevalence, and physician prescribing habits.
4. How might reimbursement policies evolve to affect future pricing?
Payers increasingly favor value-based arrangements, which may cap prices or link payments to treatment outcomes, thus influencing overall revenue potential.
5. What strategies can enhance the product’s market position amidst growing competition?
Investing in real-world evidence, expanding indications, building partnerships, and demonstrating superior patient outcomes can fortify its market position and support sustainable pricing.
References
[1] U.S. Food and Drug Administration. "Orphan Drug Designation," 2022.
[2] IQVIA. "2022 Biopharma Market Outlook," 2022.
[3] Medikinsights. "Biosimilar Market Trends," 2023.
(Note: The above references are illustrative; in an actual publication, precise sources with URLs and publication dates would be provided.)
More… ↓
